ArticleAlzheimer's research & therapy2015
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Article in Alzheimer's research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- The full spectrum of ethical issues in dementia research: findings of a systematic qualitative review.BMC medical ethics · 2021Pooled it
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- Predictors of extreme future time perspective change in persons who learn an Alzheimer's disease biomarker test result.Aging & mental health · 2026Article
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Expert consensus on communicating tau PET results to persons living with MCI or dementia: Findings from a modified Delphi study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress.JAMA network open · 2026Article
- Disclosure of onset-predictive biomarker results to research participants at risk of genetic frontotemporal dementia: a European perspective.Alzheimer's research & therapy · 2025Review
- Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Towards pharmacological prevention of Alzheimer disease.Nature reviews. Neurology · 2025Review
- Recommended approaches to sharing individual research results in Alzheimer's disease research: A multidisciplinary expert Delphi consensus.Journal of Alzheimer's disease : JAD · 2025Article
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Communicating the risk of dementia: a scoping review.BMJ neurology open · 2025Article
- Psychosocial implications of learning amyloid PET results in an observational cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Article
- Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.Neurology. Clinical practice · 2024Article
- Alzheimer's in the modern age: Ethical challenges in the use of digital monitoring to identify cognitive changes.Informatics for health & social care · 2024Article
- A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.The journal of prevention of Alzheimer's disease · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
introductionThe objective of this study was to develop a process to maximize the safety and effectiveness of disclosing Positron Emission Tomography (PET) amyloid imaging results to cognitively normal older adults participating in Alzheimer's disease secondary prevention studies such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study.
methodsUsing a modified Delphi Method to develop consensus on best practices, we gathered and analyzed data over three rounds from experts in two relevant fields: informed consent for genetic testing or human amyloid imaging.
resultsExperts reached consensus on (1) text for a brochure that describes amyloid imaging to a person who is considering whether to undergo such imaging in the context of a clinical trial, and (2) a process for amyloid PET result disclosure within such trials. Recommendations included: During consent, potential participants should complete an educational session, where they receive verbal and written information covering what is known and unknown about amyloid imaging, including possible results and their meaning, implications of results for risk of future cognitive decline, and information about Alzheimer's and risk factors. Participants should be screened for anxiety and depression to determine suitability to receive amyloid imaging information. The person conducting the sessions should check comprehension and be skilled in communication and recognizing distress. Imaging should occur on a separate day from consent, and disclosure on a separate day from imaging. Disclosure should occur in person, with time for questions. At disclosure, investigators should assess mood and willingness to receive results, and provide a written results report. Telephone follow-up within a few days should assess the impact of disclosure, and periodic scheduled assessments of depression and anxiety, with additional monitoring and follow-up for participants showing distress, should be performed.
conclusionsWe developed a document for use with potential study participants to describe the process of amyloid imaging and the implications of amyloid imaging results; and a disclosure process with attention to ongoing monitoring of both mood and safety to receive this information. This document and process will be used in the A4 Study and can be adapted for other research settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.